Calamos Advisors LLC Krystal Biotech, Inc. Transaction History

Calamos Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$96.0 - $128.29 $954,432 - $1.28 Million	-9,942 Reduced 38.76%	15,705 $1.95 Million
Q3 2023 Oct 25, 2023	BUY	$108.51 - $130.22 $546,456 - $655,787	5,036 Added 24.43%	25,647 $2.98 Million
Q2 2023 Jul 28, 2023	BUY	$78.48 - $130.32 $713,383 - $1.18 Million	9,090 Added 78.9%	20,611 $2.42 Million
Q1 2023 May 03, 2023	BUY	$72.39 - $84.27 $834,005 - $970,874	11,521 New	11,521 $922,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Calamos Advisors LLC with notifications on news.